Rainer Liedtke

'''Rainer Kurt Liedtke''' (16 September 1943 – 15 September 2012) was a German physician, scientist and entrepreneur who specialised in the theory and practice of biomedical information systems and medical innovation, and new therapies of pain, stress, cell degeneration.

== Background == Liedtke was born September 16, 1943, in Königsberg, East Prussia, and died September 15, 2012, in Grünwald, Bavaria. Doctor's degree in medicine: Biochemical studies on DNA and RNA (Institute of physiological Chemistry, University of Bonn); Institute of Pharmacology University of Bonn; Physician at hospital for several years (i. a Women Hospital University of Bonn) and initial research, i.a. by order of the German Research Foundation; Hereafter several years pharmaceutical industry (i.a. as director of clinical research at Squibb, medical director at E. Lilly), parallel work as a university lecturer for pharmacology (i.a. University of Regensburg), invited lectures (Pharmacology) at i.a. University of Frankfurt. Company founder (i.a. American Pharmed Labs, renamed to EpiCept) and its Chairman & CEO for several years.<ref>APL's progress on pain therapies; Scrip, World Pharmaceutical News, Issue No. 2375, October 2, 1998</ref> Member of various scientific associations in the areas of pharmacology, endocrinology, biological chemistry.

== Inventions and medical developments == These include biomedical information systems and a number of new transdermal therapies, e.g. transdermal hormonal contraception (1988), including its first time clinical proof (together with L. Wildt, University of Erlangen).<ref>pharmed’s oral insulin R&D / PMT patch: Scrip, World Pharmaceutical News, No 1489, February 16, 1990 p 29: "In 10 healthy volunteers the patch suppressed ovulation".</ref> Bioinformatics conception of a "transdermal therapy of neuromuscular pain" with sodium channel blockers (1993/94), including the first clinical proof of effectiveness in back pain and postoperative pain (1995) and first market product of its kind in the USA.<ref>Physician introduces pain-relief patch; The Sunday Star Ledger, New Jersey, USA, June 4, 1995.</ref> Another US product (Lidoderm) that is based on the same conception is approved for postherpetic pain. ''Transdermal beta-blockers'', including the first time clinical proof in hypertension (with W. Vetter, University of Zurich, H. Vetter, University of Bonn, W. Zidek, University of Münster (1987) and in Angina pectoris (with J. Bonelli, F. Gazo, University of Vienna (1988). Some technical basics and an actualized synopsis of these new findings have been published in a special volume of 'Drug Research' (1989).<ref>R.K. Liedtke (Edit.), Transdermaltherapie mit dem Betablocker Mepindolol (Transdermal Therapy with the Beta-blocker Mepindolol), Arzneim Forsch./ Drug Research 39 (II), 11a (1989), (ISSN 0004-4172)</ref> ''Transdermal insulin patch'' as an alternative to insulin injection, with a first time proof in preclinical studies (with K. Suwelack, K. Karzel, University of Bonn (1990)<ref>{{cite journal |vauthors=Liedtke RK, Suwelack K, Karzel K |title=Effect of peroral and transdermal insulin preparations on blood glucose concentration in mice. |journal=Arzneimittel-Forschung |year=1990 |pmid=2242079 |volume=40 |issue=8 |pages=880–3}}</ref> and in type II diabetics (with M. Sorger, H. Vetter, University of Bonn (1990).<ref>{{cite journal |vauthors=Liedtke RK, Sorger M, Merk F, Vetter H |title=Transdermal administration of insulin in type II diabetics. Results of a clinical pilot study. |journal=Arzneimittel-Forschung |date=August 1990 |pmid=2242080 |volume=40 |issue=8 |pages=884–6}}</ref> ''Antidepressive effect of oxytocin''. This has been predicted with a new biocybernetics model (1998/99), hereafter these effects were also experimentally confirmed (with I. Neumann, University of Regensburg, R. Landgraf, Max-Planck-Institute, M. Ludwig, University of Edinburgh (2000);<ref>I.D. Neumann, R.K. Liedtke, M. Ludwig, R. Langraf: Intranasally applied Oxytocin: Brain uptake and effects on neuronal functions and emotionality Summary in: International Society of PsychoNeuroEndocrinology (ISPNE) XXXI. Annual Meeting 2000, Melbourne</ref><ref>R. K. Liedtke, R. Landgraf, I. D. Neumann, Intranasally applied Oxytocin: A novel route of administration? (Poster), 1st World Congress of Women's Mental Health, Berlin 2001</ref> ''A model of a pathogenetic cell mechanism in arteriosclerosis'' (2006). Current Developments. "Intelligent" medical information systems;<ref>{{YouTube|0VcpR1qSOxs|A preliminary video introduction in the operative structure of a new internet application of a medical self-diagnosis}} (in german language)</ref> a new general theory on pain - though this was in the controversial and non-peer reviewed journal ''Medical Hypotheses''.<ref>{{cite journal |last1=Liedtke |first1=RK |title=A general theory on pain as an integrated thermodynamic mechanism |journal=Medical Hypotheses |volume=73 |issue=1 |pages=86–9 |year=2009 |pmid=19264417 |doi=10.1016/j.mehy.2009.01.026}}</ref> ''Arterial Vascular Effects of Non-steroidal Antiphlogistic Drugs''<ref>{{cite journal |author=Liedtke RK |title=A model on the induction of adverse vascular long-term effects of NSAIDs |journal=Medicinal Chemistry |volume=5 |issue=1 |pages=23–8 |date=January 2009 |pmid=19149647 |doi=10.2174/157340609787049235}}</ref> – A Biochemical Model on an Intramural Induction of Arteriosclerosis (2008).

== Author and writer == Scientific publications, medical specialist books, medical information for patients, more than 100 international patent applications (focus: drug therapy, information technology). Books: i.a. 'Introduction in drug therapy' (in German; with K. Karzel, University of Bonn),<ref>K. Karzel, R.K. Liedtke, Einführung in die Arzneimittelherapie (Grundlagen der allgemeinen Pharmakologie für Mediziner, Zahnmediziner und Pharmazeuten), G. Fischer Stuttgart/New York 2nd Edit. 1985, ({{ISBN|3-437-00425-5}})</ref> 'Dictionary of clinical pharmacology' (in German; Editor),<ref>R.K. Liedtke (Hsgb), Wörterbuch der Arzneimitteltherapie (Klinische Pharmakologie für Mediziner und Pharmazeuten), G. Fischer, Stuttgart-New York, 2nd Edit. 1985 ({{ISBN|3-437-10959-6}})</ref> Drugs – a translator for patients,<ref>[https://www.amazon.com/dp/B005E0LQOK Drugs – a translator for patients (Kindle Edition 2011)]</ref> 'Pharmacology and clinical use of ACE inhibitors' (with F. Gross, University of Heidelberg), 'Relative Intelligence'. Scripts and articles on related areas (e.g. general pharmacology, biological intelligence, artificial intelligence), critical statements on new biological developments (e.g. genomics, gene food), partly also in an own medical blog.

== References == {{Reflist}}

== External links ==

* {{DNB portal|131958119|TYP=}} * [http://www.rkliedtke.de Rainer K. Liedtke, MD] Some of the publications and patents are linked there as full text and some of the projects are described in more detail. * [https://www.ncbi.nlm.nih.gov/pubmed?term=%22Liedtke%20RK%22%5BAuthor%5D U.S. National Library of Medicine / National Institutes of Health] Citations as scientific author in the U.S. National Library of Medicine / National Institutes of Health * [http://catalogue.nla.gov.au/Record/1347543 National Library of Australia]. Pharmacology and clinical use of angiotensin I converting enzyme inhibitors : [proceedings of] First International Symposium on Captopril, Munich, May 4, 1979 / edited by Franz Gross [and] Rainer K. Liedtke * [http://blog.newlife-online.de Rainer K. Liedtke personal medical Blog]. Drugs & Therapy (in German, with translator function)

{{DEFAULTSORT:Liedtke, Rainer}} Category:1943 births Category:2012 deaths Category:German biochemists Category:Medical doctors from Königsberg